NEUPRO Drug Patent Profile

Which patents cover Neupro, and what generic alternatives are available?

Neupro is a drug marketed by Ucb Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in thirty countries.

The generic ingredient in NEUPRO is rotigotine. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rotigotine profile page.

DrugPatentWatch^® Generic Entry Outlook for Neupro

Neupro was eligible for patent challenges on May 9, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 1, 2032. This may change due to patent challenges or generic licensing.

There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEUPRO

International Patents:	72
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEUPRO

Paragraph IV (Patent) Challenges for NEUPRO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEUPRO	Extended-release Transdermal Film	rotigotine	1 mg/24 hr 2 mg/24 hr 3 mg/24 hr 4 mg/24 hr 6 mg/24 hr 8 mg/24 hr	021829	1	2013-11-26

US Patents and Regulatory Information for NEUPRO

NEUPRO is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-006	Apr 2, 2012		RX	Yes	No			Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-006	Apr 2, 2012		RX	Yes	No			Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-004	Apr 2, 2012		RX	Yes	No			Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-002	May 9, 2007		RX	Yes	No			Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-003	May 9, 2007		RX	Yes	No			Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-004	Apr 2, 2012		RX	Yes	No			Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-002	May 9, 2007		RX	Yes	No			Y

International Patents for NEUPRO

See the table below for patents covering NEUPRO around the world.

Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	025584	ПОЛИВИНИЛПИРРОЛИДОН ДЛЯ СТАБИЛИЗАЦИИ ТВЕРДОЙ ДИСПЕРСИИ НЕКРИСТАЛЛИЧЕСКОЙ ФОРМЫ РОТИГОТИНА (POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE)
South Africa	200005261	Transdermal therapeutic system which contains a D2 agonist and which is provided for treating parkinsonism and a method for the production thereof.
Canada	2767068	POLYVINYLPYRROLIDONE DESTINEE A LA STABILISATION D'UNE DISPERSION SOLIDE DE LA FORME NON CRISTALLINE DE LA ROTIGOTINE (POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE)
European Patent Office	1033978	SYSTEME THERAPEUTIQUE TRANSDERMIQUE CONTENANT UN AGONISTE D2 SERVANT A TRAITER LE SYNDROME PARKINSONIEN, ET SON PROCEDE DE PRODUCTION (TRANSDERMAL THERAPEUTIC SYSTEM WHICH CONTAINS A D2 AGONIST AND WHICH IS PROVIDED FOR TREATING PARKINSONISM, AND A METHOD FOR THE PRODUCTION THEREOF)
Israel	219091	פוליוויניל פירולידון לייצוב דיספרסיה מוצקה של צורה לא גבישית של רוטיגוטין (Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine)
Canada	2491366	SYSTEME D'ADMINISTRATION TRANSDERMIQUE AMELIORE CONCU POUR ADMINISTRER LA ROTIGOTINE (IMPROVED TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE)
Luxembourg	91269

Supplementary Protection Certificates for NEUPRO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1033978	SPC/GB06/023	United Kingdom		SPC/GB06/023: 20070702, EXPIRES: 20210214
1033978	SPC026/2006	Ireland		SPC026/2006:, EXPIRES: 20210214
1033978	CA 2006 00020	Denmark		PRODUCT NAME: ROTIGOTINE
1033978	06C0025	France		PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215
1033978	C01033978/01	Switzerland		TEILUEBERTRAGUNG
1033978	C300236	Netherlands		PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001-013 20060215
1033978	SZ 24/2006	Austria		PRODUCT NAME: ROTIGOTINE

NEUPRO (Ropinirole transdermal system): Investment scenario and fundamentals analysis

Last updated: April 25, 2026

What is NEUPRO and what is its current commercial role?

NEUPRO is ropinirole hydrochloride delivered via a transdermal patch. It is an approved treatment for Parkinson’s disease and is positioned as a chronic-care product where adherence and tolerability drive persistence.

Indications (US label)

• Treatment of Parkinson’s disease (PD)
  • Monotherapy for early PD in patients who are not receiving levodopa
  • Adjunct therapy for late PD in combination with levodopa, to treat “off” episodes
• Source: FDA label for NEUPRO (ropinirole transdermal system) (daily prescribing information) [1]

Who controls the asset and how is it protected?

NEUPRO is a branded product with a long commercial history; current protection and enforceability depend on:

• Patent estate (composition, formulation, delivery system, method-of-use)
• Regulatory exclusivity (new chemical entity exclusivity does not apply to ropinirole because the active is older; the relevant exclusivity depends on the specific transdermal system and approvals)
• Orphan/other exclusivities: none indicated in the US label

Practical investment implication

• The market for a transdermal ropinirole product is directly shaped by IP barriers to generic substitution and payer formulary placement.
• The largest long-run risk is loss of brand share if transdermal equivalents launch without meaningful enforceability.

What is the demand engine: prevalence, dosing pattern, and adherence?

Parkinson’s disease demand is driven by:

• Incidence and prevalence (aging demographics)
• Chronic therapy continuity
• Tolerability and adherence to dopamine agonist regimens

A transdermal formulation can improve:

• Adherence by removing daily oral dosing friction
• Steady delivery relative to some oral regimens, which can affect tolerability and “on-off” behavior in advanced disease

Clinical positioning that matters for fundamentals NEUPRO’s clinical value proposition is tied to PD symptom management across disease stages and to reducing daily oral dosing complexity, which supports churn resistance if payers remain comfortable with total treated costs. (Clinical claims are contained in the US prescribing information.) [1]

How does NEUPRO fit the competitive landscape?

NEUPRO competes within PD therapeutics against:

• Levodopa-based therapies
• Oral dopamine agonists
• Other dopamine agonists and adjuncts
• Device and delivery innovations that target adherence and side-effect profiles

Key competitive dynamic for investors For PD dopamine agonists, competitive pricing and formulary controls tend to determine outcomes more than marginal clinical differences once a product is established. This makes gross-to-net discipline and payer contracting decisive for long-run margin.

What does the label reveal about safety and payer-relevant risk?

NEUPRO’s risk profile shapes prior authorization scrutiny and long-term persistence.

Safety warnings and important use limitations (selected, from US label)

• Impulse control and compulsive behaviors
• Hallucinations and other psychotic-like behaviors
• Somnolence and sudden sleep
• Orthostatic hypotension and related events
• Worsening of dyskinesia (in combination settings)
• Application site reactions
• Source: NEUPRO prescribing information (high-priority warnings and adverse reactions) [1]

Investment implication

• These risks influence:
  • Formulary management
  • Prescriber selection
  • Real-world persistence
• For valuation, track adherence and discontinuation rates post-initiation, not only trial endpoints.

---

What are the commercial fundamentals and unit economics you should underwrite?

Because NEUPRO is established, investment underwriting should treat it as a mature chronic-care brand where fundamentals are dominated by:

• Net sales trajectory vs. competitors
• Gross-to-net pressure from rebates and payer demands
• Persistence and switch behavior across PD stages
• Lifecycle events (generic entry risk, label updates, procurement changes)

Core underwriting inputs

1. Demand base
   • PD treated population growth (aging cohort)
   • Share shift within dopamine agonist classes
2. Price realization
   • Contracting pressure and rebate intensity
3. Volume retention
   • Discontinuation due to adverse effects or tolerability
4. Switch dynamics
   • Movement from monotherapy to adjunct therapy with levodopa
   • Switch to competing delivery systems if they offer lower total cost or better tolerability

Label-driven dosing structure (relevant for persistence and conversion)

NEUPRO is titrated, and the label defines administration, application-site rotation, and patient guidance. The prescribing information supports a structured titration schedule and ongoing application mechanics. [1]

Investment implication

• Structured titration increases early-stage discontinuation sensitivity to adverse events; persistence impacts annual revenue more than late-stage adherence.

---

What is the regulatory and manufacturing risk profile?

Regulatory considerations

• NEUPRO is governed by ongoing quality systems and post-market safety monitoring.
• Product-specific risks in chronic transdermal systems include adhesion variability and skin reactions, which can become a real-world discontinuation driver.

Manufacturing and supply considerations

• Transdermal systems require controlled manufacturing processes for patch integrity, drug content uniformity, and device performance.
• These risks translate into:
  • Potential for supply interruptions
  • Batch quality issues that can prompt distribution constraints
• For an investor, the key is whether any manufacturing disruptions or quality actions have occurred since launch and how quickly supply normalized.

(These operational risks are consistent with the product class and are reflected in transdermal-specific label guidance and adverse reaction monitoring.) [1]

---

What does the economics scenario look like under three market paths?

Because NEUPRO is mature, the investment case should be treated as a scenario model around share stability and pricing power, not as a growth story driven by new mechanisms.

Scenario A: Share stable, price and contracting pressure continues

• Revenue growth tracks underlying PD prevalence and modest share stability
• Margins compress via gross-to-net, offset by mix stability (monotherapy-to-adjunct continuity)

Scenario B: Accelerating net price pressure or formulary exclusions

• Revenue declines as payer contracting erodes net realizations faster than volume offsets
• Increased switch to oral dopamine agonists or other reimbursed agents

Scenario C: IP or competitive entry shock

• Sales fall if transdermal ropinirole competitors launch with aggressive pricing and enforceable exclusivity barriers do not hold
• Downside concentrates in early conversion to NEUPRO and in retention after titration

Investment implication

• The highest sensitivity variables are gross-to-net, persistence, and time-to-competitor penetration.

---

Where does NEUPRO stand on pipeline momentum, risk of substitution, and lifecycle?

NEUPRO is not a “platform” in the same sense as companies building multiple late-stage candidates, but it can still generate cash if:

• The brand remains payer-preferred within PD dopamine agonist access pathways
• The patch delivery profile supports tolerability vs. oral drugs in real use

Lifecycle risks

• Transdermal competition can grow if other products offer:
  • Similar clinical outcomes
  • Better tolerability
  • Lower net prices after rebate competition
• Label expansions or tightening can shift adoption.

---

What are the practical diligence checkpoints for an investor?

Commercial diligence

• Reconcile:
  • Sales trend vs. PD prevalence trend
  • New patient starts and discontinuation rates (especially first 90-180 days)
• Confirm:
  • Formulary status in major payers
  • Rebate structure and any tightening changes

IP and litigation diligence

• Map:
  • Patent expirations tied to transdermal ropinirole composition/delivery methods
  • Any relevant regulatory exclusivities tied to the specific system approval
• Stress-test:
  • Enforceability and “at risk” volumes

Safety and pharmacovigilance diligence

• Quantify:
  • Rates of hallucinations, somnolence, orthostatic hypotension, impulse control events
  • Application-site reaction rates and discontinuation impact
• Link:
  • Safety signals to real-world persistence and payer scrutiny [1]

---

Key Takeaways

• NEUPRO is a mature ropinirole transdermal system for Parkinson’s disease with ongoing demand tied to chronic therapy adherence and tolerability. [1]
• Fundamentals are payer- and persistence-driven: gross-to-net, early discontinuation during titration, and switch behavior across PD stages determine sales trajectory more than incremental clinical positioning.
• Risk concentrates in competitive substitution and net price erosion, with the largest downside coming from transdermal competitor penetration if enforceability barriers are weak.
• Diligence should prioritize formulary access, net realization, and safety-linked persistence metrics anchored to the label’s key risks. [1]

---

FAQs

1) What is NEUPRO’s active ingredient and delivery type?

NEUPRO contains ropinirole hydrochloride delivered via a transdermal patch. [1]

2) What Parkinson’s indications does NEUPRO cover in the US?

The US label supports monotherapy for early Parkinson’s disease and adjunct therapy with levodopa for late Parkinson’s disease, including treatment of “off” episodes. [1]

3) What are the major label warnings that affect real-world adoption?

Key warning areas include impulse control and compulsive behaviors, hallucinations/psychotic-like behaviors, somnolence/sudden sleep, orthostatic hypotension, and worsening dyskinesia in combination contexts, plus application-site reactions. [1]

4) Why does dosing titration matter for investor fundamentals?

Titration and early tolerability determine time-to-therapy success and initial persistence, which can drive annual sales more than later-stage demand for an established brand. [1]

5) What is the highest practical competitive risk for NEUPRO?

The highest risk is loss of payer share through substitution to other reimbursed PD therapies or transdermal competitors, especially if net pricing pressure accelerates. Label and class risk factors also influence persistence and discontinuation. [1]

---

References

[1] U.S. Food and Drug Administration. (n.d.). Neupro (ropinirole) transdermal system prescribing information (label). FDA. https://www.accessdata.fda.gov/